Clinical Trial Update: SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction [Phase 2]

View source ↗

Summary

SAR407899 was studied as a single-dose treatment for mild-to-moderate erectile dysfunction in a Phase 2 trial that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erectile Dysfunction

Drugs mentioned

• SAR407899

Snippet

Sponsor: Sanofi | Conditions: Erectile Dysfunction | Phase 2 | Status: COMPLETED